Judicial oversight maintained in teenager’s gender transition case

A mother’s legal effort to prevent her teenage child from receiving cross-sex hormones for gender transition has been successful in ensuring continued judicial oversight of the matter. The Court of Appeal determined that it is “appropriate” for the judiciary to “keep an eye” on the proceedings, given the swift evolution of gender services and their regulatory framework. The court affirmed that the 16-year-old possesses the capacity and competence to consent to hormone treatment designed to foster male physical characteristics. Nevertheless, it indicated that a future judicial determination might be required regarding whether such treatment aligns with the young person’s best interests. Typically, individuals between the ages of 16 and 18, despite not having reached legal adulthood, are generally considered capable of making independent medical decisions. Cross-sex hormone therapy facilitates an individual’s transition to a gender different from their birth sex. In delivering the judgment, Sir Geoffrey Vos, the Master of the Rolls, recognized the potential distress and disruption the teenager might experience due to the continuing legal process, but expressed his hope that they “will come quickly to realise that we have pre-judged nothing”. The young individual, identified as “Q” in court, is presently undergoing an assessment at a private gender clinic. For legal reasons, the family’s identity cannot be disclosed. The mother issued a statement, describing the preceding two years as “painful, exhausting and terrifying,” and indicating that this judicial decision instilled hope for her child’s future. Paul Conrathe, her legal representative, characterized the judgment as a “significant ruling,” asserting that “it can no longer be assumed that just because a young person is 16 years old, intelligent and in good health that their decision to proceed with cross-sex hormones is the end of the matter”. This development marks the most recent turn in a complex and protracted legal dispute. The teenager, assigned female at birth, seeks to transition to male, a process for which cross-sex hormone treatment would facilitate the development of masculine physical traits like a deeper voice and facial hair. The parents underwent an acrimonious divorce, with the father supporting the teenager’s desire for private gender-affirming treatment. The mother has financed a two-year legal challenge against this through crowdfunding. Her initial case was rejected by a lower court in April, a decision that would have concluded judicial involvement in the matter. The mother’s appeal was adjudicated by a three-judge panel, led by the Master of the Rolls, and including Sir Andrew McFarlane, president of the family courts, and Lady Justice King. Indicating significant public interest, the one-day hearing held on 11 December was livestreamed. The judgment issued today noted the unlikelihood of parental agreement in the case, deeming it prudent to maintain the ongoing proceedings because “there is sufficient current doubt as to what is proper and appropriate in this area”. The court determined that the judge in the previous instance “did not place enough weight on the possibility of genuine future disagreement, the rapidly changing regulatory environment and the fact that services provided by private hormone clinics seem already to be in a somewhat different position from the same services provided by the NHS”. The Cass Review, released in April of this year, identified a scarcity of research and “weak evidence” supporting medical interventions in gender care. Consequently, NHS England instructed all NHS gender clinics to exercise “extreme caution” before recommending cross-sex hormones for individuals under 18. The Cass Review additionally outlined a framework for a significant overhaul of NHS-operated services, involving the establishment of new multi-disciplinary clinics. A key recommendation was that a national multi-disciplinary team (MDT) should review every case considered for medical treatment. The court raised concerns about the practicability of this for a private clinic. In the UK, Gender Plus operates as the sole privately-run regulated gender hormone clinic. It recently achieved an “outstanding” rating subsequent to its inaugural inspection by the Care Quality Commission, its regulatory body. A distinct division of the clinic conducts assessments. The teenager is currently engaged in a six-month series of interviews with this team, preceding any recommendations regarding referral to the hormone clinic. Dr. Aidan Kelly, a clinical psychologist and director at Gender Plus, stated that while he was unable to comment on individual cases, all young individuals deemed suitable for gender-affirming hormones ought to be reviewed by a panel of clinicians not directly involved in their treatment. He explained that since the clinic cannot utilize the NHS national panel, it has established its own. He further elaborated, “The MDT, which includes an independent child and adolescent psychiatrist, must review all referrals prior to being accepted onto the hormone pathway.” The court has adjourned the case involving “Q,” indicating that this action permits its renewed involvement should circumstances necessitate it.